Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERNA Ernexa Therapeutics	$1.51 -1.0%	$1.91	$1.48 ▼ $28.80	$11.54M	5.42	302,838 shs	69,858 shs
KPTI Karyopharm Therapeutics	$6.42 +6.6%	$4.49	$3.51 ▼ $16.95	$55.54M	0.28	127,320 shs	82,328 shs
MAAQ Mana Capital Acquisition	$3.50 -4.6%	$3.93	$5.35 ▼ $10.25	$28.44M	N/A	33,075 shs	29,645 shs
STTK Shattuck Labs	$0.96 +6.7%	$0.86	$0.69 ▼ $3.95	$45.74M	1.63	845,971 shs	412,028 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERNA Ernexa Therapeutics	-1.94%	-6.17%	-24.38%	-55.56%	-94.37%
KPTI Karyopharm Therapeutics	-7.38%	+29.46%	+54.76%	+31.15%	-50.41%
MAAQ Mana Capital Acquisition	-4.63%	-6.42%	-18.60%	-17.45%	+677.95%
STTK Shattuck Labs	-11.42%	+3.99%	+11.48%	-17.16%	-73.92%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERNA Ernexa Therapeutics	0.3814 of 5 stars	0.0	3.0	0.0	0.0	1.2	1.7	0.0
KPTI Karyopharm Therapeutics	3.9081 of 5 stars	3.4	0.0	0.0	4.6	2.5	2.5	0.6
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	3.5582 of 5 stars	3.4	5.0	0.0	0.0	2.5	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERNA Ernexa Therapeutics	0.00	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$34.00	429.60% Upside
MAAQ Mana Capital Acquisition	0.00	N/A	N/A	N/A
STTK Shattuck Labs	2.83	Moderate Buy	$7.00	632.98% Upside

Current Analyst Ratings Breakdown

Latest ERNA, STTK, MAAQ, and KPTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	STTK Shattuck Labs	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$4.00 ➝ $2.00
8/14/2025	STTK Shattuck Labs	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/12/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$42.00 ➝ $25.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERNA Ernexa Therapeutics	$580K	19.90	N/A	N/A	$0.58 per share	2.59
KPTI Karyopharm Therapeutics	$137.27M	0.41	N/A	N/A	($27.55) per share	-0.23
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	$5.72M	8.00	N/A	N/A	$1.19 per share	0.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERNA Ernexa Therapeutics	-$44.54M	-$8.31	N/A	∞	N/A	-7,652.75%	N/A	-682.08%	11/10/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$14.59	N/A	N/A	N/A	-90.02%	N/A	-84.28%	11/4/2025 (Estimated)
MAAQ Mana Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	-$75.41M	-$1.21	N/A	N/A	N/A	N/A	-81.80%	-71.46%	N/A

Latest ERNA, STTK, MAAQ, and KPTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	STTK Shattuck Labs	-$0.25	-$0.24	+$0.01	-$0.24	N/A	N/A
8/13/2025	Q2 2025	ERNA Ernexa Therapeutics	N/A	-$0.61	N/A	-$0.61	N/A	N/A
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
STTK Shattuck Labs	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERNA Ernexa Therapeutics	N/A	1.81	1.81
KPTI Karyopharm Therapeutics	N/A	0.99	0.94
MAAQ Mana Capital Acquisition	N/A	N/A	N/A
STTK Shattuck Labs	N/A	10.25	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERNA Ernexa Therapeutics	70.55%
KPTI Karyopharm Therapeutics	66.44%
MAAQ Mana Capital Acquisition	68.44%
STTK Shattuck Labs	58.74%

Insider Ownership

Company	Insider Ownership
ERNA Ernexa Therapeutics	1.50%
KPTI Karyopharm Therapeutics	2.98%
MAAQ Mana Capital Acquisition	N/A
STTK Shattuck Labs	12.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERNA Ernexa Therapeutics	10	7.67 million	7.56 million	No Data
KPTI Karyopharm Therapeutics	380	8.67 million	8.41 million	Optionable
MAAQ Mana Capital Acquisition	1	8.13 million	N/A	Not Optionable
STTK Shattuck Labs	100	47.90 million	42.16 million	Optionable

ERNA, STTK, MAAQ, and KPTI Headlines

Recent News About These Companies

Shattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

5 hours ago | finanznachrichten.de

Shattuck Labs Reports Q2 2025 Financial Results

5 hours ago | msn.com

Shattuck Labs says IND for SL-325 for treatment of IBD in effect

5 hours ago | msn.com

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

August 21 at 10:17 AM | globenewswire.com

Shattuck Labs raises up to $103M to fund therapeutic antibody development

August 19 at 7:07 PM | ncbiotech.orgN

Shattuck Labs, Inc. (NASDAQ:STTK) Given Average Recommendation of "Moderate Buy" by Brokerages

August 19 at 2:09 AM | americanbankingnews.com

Leerink Partnrs Estimates Shattuck Labs Q1 Earnings

August 18, 2025 | americanbankingnews.com

Shattuck Labs' (STTK) "Hold" Rating Reiterated at Needham & Company LLC

August 17, 2025 | americanbankingnews.com

Shattuck Labs (NASDAQ:STTK) Price Target Lowered to $2.00 at Leerink Partners

August 16, 2025 | americanbankingnews.com

Shattuck Labs price target lowered to $2 from $4 at Leerink

August 14, 2025 | msn.com

Shattuck Labs Submits IND Application for SL-325; Phase 1 Trial in Healthy Volunteers Expected to Begin Q3 2025

August 14, 2025 | quiverquant.comQ

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 14, 2025 | globenewswire.com

Shattuck Labs expects $103 million from private placing

August 6, 2025 | thepharmaletter.comT

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

August 5, 2025 | globenewswire.com

Shattuck Labs Elects Directors, Approves Auditor at Meeting

July 15, 2025 | tipranks.com

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

July 2, 2025 | globenewswire.com

Shattuck Labs, Inc. (STTK) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Here's Why We're Watching Shattuck Labs' (NASDAQ:STTK) Cash Burn Situation

June 13, 2025 | finance.yahoo.com

Shattuck Labs Advances SL-325 Program Amid Financial Progress

May 5, 2025 | tipranks.com

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ERNA, STTK, MAAQ, and KPTI Company Descriptions

Ernexa Therapeutics NASDAQ:ERNA

$1.50 -0.02 (-0.99%)

As of 03:24 PM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Karyopharm Therapeutics NASDAQ:KPTI

$6.42 +0.40 (+6.64%)

As of 03:24 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Mana Capital Acquisition NASDAQ:MAAQ

$3.50 -0.17 (-4.63%)

As of 08/20/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

Shattuck Labs NASDAQ:STTK

$0.96 +0.06 (+6.74%)

As of 03:25 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time